The document discusses the growing challenges and costs associated with specialty drugs, which represent a significant portion of U.S. drug expenditures. It highlights the disproportionate increase in specialty drug spending, along with the complexities faced by patients, providers, and payers in managing these therapies. The document emphasizes the necessity for robust coordination of care and effective strategies to enhance patient adherence and overall treatment outcomes.